|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured the frequencies of circulating myeloid (mDC) and plasmacytoid (pDC) dendritic cells and IFN-α production along with the expression of DC-SIGN and Toll Like Receptors (TLR's) in HBV patients at different time points.
|
27658394 |
2016 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR.
|
27793564 |
2016 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Viral genotype and hepatitis B surface antigen (HBsAg) decline were the most important predictive factor for PEG-IFN response.
|
27017932 |
2016 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 39 single nucleotide polymorphism loci in 23 genes of the TLR-IFN pathway and four HLA polymorphism loci associated with chronic HBV infection identified by GWAS were selected for genotyping.
|
25469587 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122).
|
25914481 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with PEG-IFN monotherapy were enrolled in this study.
|
24517415 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hepatitis B serological markers and viral loads were tested every 3 months until 1 year after stopping Peg-IFN therapy.
|
25835020 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, in HBV several retrospective studies yielded conflicting results of the association of IL28B with PEG-IFN-induced treatment response.
|
26284971 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 30 patients with CHB who achieved HBsAg seroclearance following peg-IFN-α therapy and an additional 30 age-, gender-, hepatitis B e antigen (HBeAg) status- and hepatitis B virus genotype-matched patients with CHB without HBsAg seroclearance following peg-IFN-α therapy, were enrolled as a discovery cohort.
|
25324041 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the polymorphic variant of IFNA1 (-2) gene is associated with chronic HBV infection, and high expression levels of the IFNAR1 gene and low levels of IFNA1 might contribute to the pathogenesis of chronic infection in these subjects.
|
27101083 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study was conducted to determine whether polymorphisms near or in interferon-lambda (IFN-λs) genes and their receptor genes such as interleukin 28 receptor, alpha (IL28RA) and interleukin 10 receptor, beta (IL10RB) as well as p21-activated kinases 4 (PAK4) and iron/zinc purple acid phosphatase-like protein (PAPL), which are locate upstream of IFN-λs, and lastly the DEPDC5 gene are associated with hepatitis B virus-related liver disease in Han Chinese.
|
25032264 |
2014 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vitro IFN-λ1 treatment of Hep3B and Huh7 human hepatoma cell lines increased MHC class I expression, activated JAK-STAT signaling pathways, induced IFN-stimulated gene expression, and inhibited hepatitis B surface antigen (HBsAg) expression.
|
24769671 |
2014 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For HBeAg-positive patients and HBeAg-negative patients with genotype D infection, PEG-IFN therapy could be terminated early at week 12 or 24 in primary non-responders defined by the Hepatitis B surface antigen stopping rules.
|
24738850 |
2014 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicated that the expression of the innate immune factors MOV10, A3G, and IFN-α is affected by chronic HBV infection.
|
24871977 |
2014 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection.
|
23907803 |
2014 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The main advantages of IFN-α over nucleoside analogues are the absence of resistance and the possibility of immune-mediated clearance of hepatitis B.
|
23286858 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
By multifactor dimensionality reduction analysis, we found the interaction between IFNA5 (-2529) and IFNA1 (-1823) genes that gave the risk to chronic HBV infection, with the OR (95% CI) of the high-risk to low-risk group was 2.79 (1.77-4.40), P < 0.0001.
|
23566196 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
To explore the predictive role of serum quantitative HBsAg in predicting treatment response towards IFNα-1b in hepatitis B e antigen-positive chronic hepatitis B patients.
|
23411867 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, these sustained response rates can be significantly increased by carefully selecting candidates for PEG-IFN therapy based upon baseline ALT and HBV DNA levels, viral genotype and IL28B polymorphisms, by extending PEG-IFN therapy beyond 48 weeks and, most importantly, by applying early on-treatment stopping rules based upon HBsAg kinetics.
|
23286860 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
We treated 92 chronic hepatitis B patients (44 hepatitis B e antigen [HBeAg]-positive and 48 HBeAg-negative) with HBV DNA > 100,000 copies/ml (> 17,182 IU/ml) with PEG-IFN and adefovir for 48 weeks and followed them up for 2 years.
|
23639931 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the study is to investigate whether SNPs in JAK1 were associated with outcomes of HBV infection and response to IFNα therapy.
|
22901011 |
2012 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We confirmed in two independent studies that the combination of HBsAg and HBV DNA levels at week 12 identifies HBeAg-negative patients with a very low chance of SR to either 48 or 96 weeks of PEG-IFN therapy.
|
22245886 |
2012 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated whether HBV infection reduced IFN-α-mediated induction of antiviral defense mechanisms in human hepatocytes.
|
21376046 |
2011 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with lower doses and shorter durations, the licensed PEG-IFNα-2a treatment regimen (180 μg/48 weeks) was the most efficacious and beneficial for HBeAg-positive patients predominantly infected with hepatitis B virus genotypes B or C.
|
22045673 |
2011 |